Food-Borne Clenbuterol May Have Potential for Cardiovascular Effects with Chronic Exposure (Commentary)

REFERENCES

• Mitchell G. A., Dunnavan G. Illegal Use of Beta-Adrenergic Agonists in the United States. J. Anim. Sci. 1998; 76: 208–211
   PubMed Web of Science ®Google Scholar
• Kuiper H. A., Noordam M. Y., van Dooren-Flipsen M. M., Schilt R., Roos A. H. Illegal Use of Beta-Adrenergic Agonists: European Community (Review). J. Anim. Sci. 1998; 76: 195–207
   PubMed Web of Science ®Google Scholar
• Chan T. Y.K. Health Hazards Due to Clenbuterol Residues in Food. J. Toxicol. Clin. Toxicol. 1999; 37: 517–519
   PubMed Web of Science ®Google Scholar
• Palmer R. M., Delday M. I., McMillan D. N., Noble B. S., Bain P., Maltin C. A. Effects of the Cyclo-Oxygenase Inhibitor, Fenbufen, on Clenbuterol-Induced Hypertrophy of Cardiac and Skeletal Muscle of Rats. Br. J. Pharmacol. 1990; 101: 835–838
   PubMed Web of Science ®Google Scholar
• Petrou M., Wynne D. G., Boheler K. R., Yacoub M. H. Clenbuterol Induces Hypertrophy of the Latissimus dorsi Muscle and Heart in the Rat with Molecular and Phenotypic Changes. Circulation 1995; 92(9 Suppl)II483–II489
   PubMedGoogle Scholar
• Wong K., Boheler K. R., Bishop J., Petrou M., Yacoub M. H. Clenbuterol Induces Cardiac Hypertrophy with Normal Functional, Morphological and Molecular Features. Cardiovasc. Res. 1998; 37: 115–122
   PubMed Web of Science ®Google Scholar
• Cubria J. C., Reguera R., Balana-Fouce R., Ordonez C., Ordonez D. Polyamine-Mediated Hypertrophy Induced by Clenbuterol in the Mouse. J. Pharm. Pharmacol. 1998; 50: 91–96
   PubMed Web of Science ®Google Scholar
• Von Deutsch D. A., Abukahalaf I. K., Wineski L. E., Aboul-Enein H. Y., Pitts S. A., Parks B. A., Oster R. A., Paulsen D. F., Potter D. E. Beta-Agonist Induced Alterations in Organ Weights and Protein Content: Comparison of Racemic Clenbuterol and Its Enantiomers. Chirality 2000; 12: 637–648
   PubMed Web of Science ®Google Scholar
• Yang Y. T., McElligott M. A. Multiple Actions of β- Adrenergic Agonists on Skeletal Muscle and Adipose Tissue. Biochem. J. 1989; 261: 1–10
   PubMed Web of Science ®Google Scholar
• Kennedy M. C. Newer Drugs Used to Enhance Sporting Performance. Med. J. Aust. 2000; 173: 314–317
   PubMed Web of Science ®Google Scholar
• Prather I. D., Brown D. E., North P., Wilson J. R. Clenbuterol: A Substitute for Anabolic Steroids?. Med. Sci. Sports Exercise 1995; 27: 1118–1121
   PubMed Web of Science ®Google Scholar
• Nieminen M. S., Rämo M. P., Viitasalo M., Heikkila P., Karjalainen J., Mantysaari M., Heeikkila J. Serious Cardiovascular Side Effects of Large Doses of Anabolic Steroids in Weight Lifters. Eur. Heart J. 1996; 17: 1576–1583
   PubMed Web of Science ®Google Scholar
• Goldstein D. R., Dobbs T., Krull B., Plumb V. J. Clenbuterol and Anabolic Steroids: A Previously Unreported Cause of Myocardial Infarction with Normal Coronary Arteriograms. South. Med. J. 1998; 91: 780–784
   PubMed Web of Science ®Google Scholar
• Hartung R., Gerth J., Fünfstück R., Gröne H.-J., Stein G. End-Stage Renal Disease in a Bodybuilder: A Multifactorial Process or Simply Doping? Nephrol. Dial. Transplant. 2001; 16: 163–165
   Web of Science ®Google Scholar
• Dickerman R. D., Schaller F., McConathy W. J. Left Ventricular Wall Thickening Does Occur in Elite Power Athletes with or without Anabolic Steroid Use. Cardiology 1998; 90: 145–148
   PubMed Web of Science ®Google Scholar
• Brown D. W., Giles W. H., Croft J. B. Left Ventricular Hypertrophy as a Predictor of Coronary Heart Disease Mortality and the Effect of Hypertension. Am. Heart J. 2000; 140: 848–856
   PubMed Web of Science ®Google Scholar
• Novo S., Barbagallo M., Abrignani M. G., Nardi E., Di Maria G. U., Longo B., Mistretta A., Strano A. Increased Prevalence of Cardiac Arrhythmias and Transient Episodes of Myocardial Ischemia in Hypertensives with Left Ventricular Hypertrophy but Without Clinical History of Coronary Heart Disease. Am. J. Hypertens. 1997; 10: 843–851
   PubMed Web of Science ®Google Scholar
• Duncker D. J., Bache R. J. Effect of Chronotropic and Inotropic Stimulation on the Coronary Pressure Flow Relation in Left Ventricular Hypertrophy. Basic Res. Cardiol. 1997; 92: 271–286
   PubMed Web of Science ®Google Scholar
• Bouvy M. L., Heerdink E. R., De Bruin M. L., Herings R. M., Leufkens H. G., Hoes A. W. Use of Sympathomimetic Drugs Leads to Increased Risk of Hospitalization for Arrhythmias in Patients with Congestive Heart Failure. Arch. Intern. Med. 2000; 160: 2477–2480
   PubMed Web of Science ®Google Scholar
• Mogilnicka E., Kilmek V., Nowak G., Czyrak A. Clonidine and Beta-Agonists Induce Hyperthermia in Rats at a High Ambient Temperature. J. Neural. Transm. 1985; 63: 223–235
   PubMed Web of Science ®Google Scholar
• Gonzalez-Alonso J. Separate and Combined Influences of Dehydration and Hyperthermia on Cardiovascular Responses to Exercise. Int. J. Sports Med. 1998; 19(Suppl 2)S111–S114
   PubMed Web of Science ®Google Scholar
• Parssinen M., Kujala U., Vartiainen E., Sarna S., Seppala T. Increased Premature Mortality of Competitive Powerlifters Suspected to Have Used Anabolic Agents. Int. J. Sports Med. 2000; 21: 225–227
   PubMed Web of Science ®Google Scholar
• Sullivan M. L., Martinez C. M., Gennis P., Gallagher E. J. The Cardiac Toxicity of Anabolic Steroids Prog. Cardiovasc. Dis. 1998; 41: 1–15
   Google Scholar
• Choo J. J., Horan M. A., Little R. A., Rothewell N. J. Anabolic Effects of Clenbuterol on Skeletal Muscle Are Mediated by Beta-2-Adrenoreceptor Activation. Am. J. Physiol. 1992; 263: E50–E56
   PubMed Web of Science ®Google Scholar
• Meyer H. H., Rinke L. M. The Pharmacokinetics and Residues of Clenbuterol in Veal Calves. J. Anim. Sci. 1991; 69: 4538–4544
   PubMed Web of Science ®Google Scholar
• Sporano V., Grasso L., Esposito M., Oliviero G., Brambilla G., Loizzo A. Clenbuterol Residues in Non-Liver Containing Meat as a Cause of Collective Food Poisoning. Vet. Hum. Toxicol. 1998; 40: 141–143
   PubMedGoogle Scholar
• Brambilla G., Cenci T., Franconi F., Galarini R., Macri A., Rondoni F., Strozzi M., Loizzo A. Clinical and Pharmacological Profile in a Clenbuterol Epidemic Poisoning of Contaminated Beef Meat in Italy. Toxicol. Lett. 2000; 114: 47–53
   PubMed Web of Science ®Google Scholar
• Pulce C., Lamaison D., Keck G., Bostvironnois C., Nicolas J., Descotes J. Collective Human Food Poisonings by Clenbuterol Residues in Veal Liver. Vet. Hum. Toxicol. 1991; 33: 480–481
   PubMedGoogle Scholar
• Shiu T. C., Chong Y. H. A Cluster of Clenbuterol Poisoning Associated with the Pork and Pig Offal in Hong Kong. Public Health Epidemiol. Bull. (Hong Kong) 2001; 10: 14–17
   Google Scholar
• Martinez-Navarro J. F. Food Poisoning Related to Consumption of Illicit β-Agonist in Liver (Letter). Lancet 1990; 336: 1311
   PubMed Web of Science ®Google Scholar
• Elliott C. T., McCaughey W. J., Shortt H. D. Residues of the Beta-Agonist Clenbuterol in Tissues of Medicated Farm Animals. Food Addict. Contam. 1993; 10: 231–244
   PubMed Web of Science ®Google Scholar
• Smith D. J., Paulson G. D. Distribution, Elimination, and Residues of [14C]Clenbuterol HCl in Holstein Calves. J. Anim. Sci. 1997; 75: 454–461
   PubMed Web of Science ®Google Scholar
• Whitsett T. L., Manion C. V., Wilson M. F. Cardiac, Pulmonary and Neuromuscular Effects of Clenbuterol and Terbutaline Compared with Placebo. Br. J. Clin. Pharmacol. 1981; 12: 195–200
   PubMed Web of Science ®Google Scholar
• Su W. J., Perng R. P. Spiropent (Clenbuterol): Another Choice for Patients with Chronic Reversible Airways Obstruction. Chung Hua I Hsueh Tsa Chih 1991; 47: 13–17
   Google Scholar